{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ESTRING&page=2",
    "query": {
      "intervention": "ESTRING",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ESTRING&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T00:53:56.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02885454",
      "title": "To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Drospirenone/ethinylestradiol",
          "type": "DRUG"
        },
        {
          "name": "AL-335",
          "type": "DRUG"
        },
        {
          "name": "Odalasvir (ODV)",
          "type": "DRUG"
        },
        {
          "name": "Simeprevir (SMV)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2016-08",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-23",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02885454"
    },
    {
      "nct_id": "NCT00030654",
      "title": "Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "estramustine phosphate sodium",
          "type": "DRUG"
        },
        {
          "name": "flutamide",
          "type": "DRUG"
        },
        {
          "name": "ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "releasing hormone agonist therapy",
          "type": "DRUG"
        },
        {
          "name": "vinblastine sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 21,
      "start_date": "2002-10",
      "completion_date": "2005-02-04",
      "has_results": false,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 75,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 63 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Martinez",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030654"
    },
    {
      "nct_id": "NCT00370019",
      "title": "Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Premature Ovarian Failure"
      ],
      "interventions": [
        {
          "name": "Estradiol/Medroxyprogesterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2006-08-25",
      "completion_date": "2011-12-12",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00370019"
    },
    {
      "nct_id": "NCT05282277",
      "title": "Examining the Effects of Estradiol on Neural and Molecular Response to Reward",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression",
        "Psychosis",
        "Anhedonia"
      ],
      "interventions": [
        {
          "name": "Transdermal Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Micronized Progesterone",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo Patch",
          "type": "DRUG"
        },
        {
          "name": "Raclopride C11",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 55 Years · Female only"
      },
      "enrollment_count": 103,
      "start_date": "2022-04-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05282277"
    },
    {
      "nct_id": "NCT00417430",
      "title": "Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "ICI 182,780 (Faslodex)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Center for Rheumatic Disease, Allergy, & Immunology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 50 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2004-09",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2009-09-22",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00417430"
    },
    {
      "nct_id": "NCT04923867",
      "title": "Suturable DuraGen™ PMCF Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cerebrospinal Fluid Leak"
      ],
      "interventions": [
        {
          "name": "Suturable DuraGen™",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Integra LifeSciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 106,
      "start_date": "2021-04-28",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Jacksonville, Florida • Portland, Oregon",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04923867"
    },
    {
      "nct_id": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER2-positive Metastatic Breast Cancer",
        "KRAS Mutant Metastatic Colorectal Cancer",
        "Metastatic Lung Cancer",
        "Metastatic Colorectal Cancer",
        "Advanced Lung Cancer",
        "HR-positive, HER2-negative Advanced Breast Cancer",
        "HER2-positive Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BBO-10203",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 392,
      "start_date": "2024-10-29",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 19,
      "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06625775"
    },
    {
      "nct_id": "NCT05768139",
      "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Solid Tumors, Adult"
      ],
      "interventions": [
        {
          "name": "STX-478",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Imlunestrant",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 880,
      "start_date": "2023-04-17",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 28,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05768139"
    },
    {
      "nct_id": "NCT00083005",
      "title": "Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "estramustine phosphate sodium",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2004-03",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00083005"
    },
    {
      "nct_id": "NCT03815929",
      "title": "Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiovascular Risk Reduction"
      ],
      "interventions": [
        {
          "name": "Estradiol 100 Micrograms Patch",
          "type": "DRUG"
        },
        {
          "name": "Estradiol Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 45 Years · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2019-03-15",
      "completion_date": "2023-08-28",
      "has_results": true,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-09-09T00:53:56.606Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03815929"
    }
  ]
}